Evidence map›Paper›PMID 40297769›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025

Reduced Weight Gain with Pioglitazone vs Vildagliptin in

Zanetta L L Toomata, Yannan Jiang, Rui Qian Yeu, Rebecca Brandon, Ry Yves Tweedie-Cullen, Norma Nehren, Glenn Doherty, Huti Watson, Kerry A Macaskill-Smith, Megan Leask and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zanetta L L ToomataDepartment of Medicine, Faculty of Medical and Health Sciences, the University of Auckland, Auckland, New Zealand.ORCID 0000-0001-6381-9185
Yannan JiangDepartment of Statistics, Faculty of Sciences, the University of Auckland, Auckland, New Zealand.
Rui Qian YeuTe Whatu Ora Te Toka Tumai Auckland, Auckland District Health Board, Auckland, New Zealand.
Rebecca BrandonDefence Health Centre, Waiouru, New Zealand.
Ry Yves Tweedie-CullenDepartment of Medicine, Faculty of Medical and Health Sciences, the University of Auckland, Auckland, New Zealand.
Norma NehrenTe Hiku Hauora, Kaitaia, Northland District Health Board, Kaitaia, New Zealand.
Glenn DohertyTongan Health Society, Auckland, New Zealand.
Huti WatsonNgāti Porou Oranga Trust (A Māori Health Provider), Te Puia Springs, Gisborne, New Zealand.
Kerry A Macaskill-SmithFairfield Medical Centre, Hamilton, New Zealand.
Megan LeaskMaurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand.
Tony R MerrimanDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ryan PaulMaurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand.
Troy L MerryMaurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand.
Peter R ShepherdMaurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand.
Rinki MurphyDepartment of Medicine, Faculty of Medical and Health Sciences, the University of Auckland, Auckland, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Objectives: This subgroup analysis of a randomised, open-label, two-period crossover trial in Aotearoa New Zealand (February 2019 to March 2020) assessed whether the glucose-lowering effects of vildagliptin, vs pioglitazone varied by the Methods: Adults with type 2 diabetes and HbA1c > 58 mmol/mol (>7.5%) received either pioglitazone (30 mg) or vildagliptin (50 mg) for 16 weeks, then switched medications for another 16 weeks. Differences in HbA1c between treatments (pioglitazone vs vildagliptin) were tested for an interaction with Results: Participants with the AA/AG genotype had a higher baseline weight than those with the GG genotype (121.4 kg vs 106.6 kg, respectively; Conclusion:

Indexed as

CREBRFpharmacogeneticspioglitazoneprecision medicinestratified drug responsevildagliptin

Identifiers

PMID40297769
PMCPMC12035406

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.